Haisco Pharmaceutical to unlock 1.74m restricted shares for key staff

Haisco Pharmaceutical Group Co., Ltd. announced the first unlock period for its 2024 restricted stock incentive plan, with 1,740,000 restricted shares set to become tradable. This represents 0.1554% of the company's current total share capital. These shares, allocated to six core business technical personnel, will be listed and circulated on November 19, 2025.

The unlock follows the fulfillment of performance conditions, including the company's 2024 operating revenue of 3.721 bn yuan and 13 IND applications for drugs being declared and accepted. Additionally, all six incentive recipients achieved an "excellent" rating in their individual performance assessments, qualifying for a 100% unlock ratio.

The incentive plan's reservation grant price was adjusted from 14.10 yuan per share to 13.955 yuan per share, effective from September 19, 2024, following the company’s 2024 semi-annual equity distribution plan. This adjustment was within the authority granted by the 2024 first extraordinary general meeting of shareholders.